Bukwang Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 49,643.69 million compared to KRW 47,824.72 million a year ago. Net loss was KRW 693.34 million compared to net income of KRW 657.42 million a year ago. Basic loss per share from continuing operations was KRW 10 compared to basic earnings per share from continuing operations of KRW 10 a year ago. Diluted loss per share from continuing operations was KRW 10 compared to diluted earnings per share from continuing operations of KRW 10 a year ago. Basic loss per share was KRW 10 compared to basic earnings per share of KRW 10 a year ago.
For the nine months, negative sales was KRW 0.00077 million compared to sales of KRW 0.00025 million a year ago. Net loss was KRW 3,235.15 million compared to KRW 2,825.56 million a year ago. Basic loss per share from continuing operations was KRW 47 compared to KRW 41 a year ago. Diluted loss per share from continuing operations was KRW 47 compared to KRW 41 a year ago. Basic loss per share was KRW 47 compared to KRW 41 a year ago.